Except for one protective variant (MTHFR rs1801133) for prostate cancer (OR = 0.684, 95% c.i.=0.565–0.828), six of the seven variant (in MGMT, XRCC1, OGG1, ERCC2 and CASC8) showed risks for prostate cancer. Here, ERCC2 is linked to prostate carcinoma.